Serina Therapeutics Inc (SER) is a clinical-stage biopharmaceutical company developing drug delivery candidates built on its proprietary POZ (polyoxazoline) polymer platform. The company has no approved products and generates no product revenue as of its 10-K filed 2026-03-25. Serina's platform centers on POZ as an alternative to PEG (polyethylene glycol) for drug conjugation, with preclinical and early clinical data indicating higher drug loading capacity, programmable release kinetics, non-immunogenicity, and renal clearance without tissue accumulation. Its proof-of-principle molecule, SER-214, was the first POZ-based compound tested in humans, showing no toxicity concerns in that trial. The company is pursuing development in the CNS and drug delivery fields, with pipeline programs in preclinical and clinical stages. Serina holds granted U.S. patent 11,766,432 (granted September 26, 2023, expiring July 27, 2039) and multiple international applications covering its POZ technology. The company relies on external funding to advance its pipeline toward regulatory approval.

Revenue model

Serina Therapeutics has no approved products and no product revenue as of the 10-K filed 2026-03-25. The company is pre-commercial and depends on external capital to fund research, development, and clinical operations. Future revenue, if any, would come from product sales, licensing arrangements, or collaboration agreements, none of which are confirmed in the filing excerpts.

Products and services

POZ polymer drug delivery platform, used for conjugating small molecule drugs to the polyoxazoline backbone with high drug loading (n=10 or higher attachment points per polymer chain). SER-214 is the proof-of-principle clinical molecule, representing the first human use of POZ polymer. Pipeline programs are in the CNS and drug delivery fields, with preclinical and early clinical stage assets. No products are approved or commercialized as of the filing date.

Customers and end markets

Target end markets include patients and physicians in CNS disorders and other therapeutic areas requiring controlled drug delivery. Commercial customers would include patients, hospitals, and third-party payors including government health programs in the U.S. and internationally. No commercial customers exist as of the 10-K filed 2026-03-25.

Value-chain role

Drug discovery and development company operating at the research, preclinical, and early clinical stages of the pharmaceutical value chain. Serina conducts preclinical studies, IND-enabling studies, and clinical trials internally and through third parties. Manufacturing, sales, and distribution are not yet established; the company has indicated it may use third-party contractors or collaboration partners for commercialization if products reach approval.

Geographic exposure

Serina holds patent applications across the U.S., Australia, Canada, China, Hong Kong, Europe, Israel, Japan, South Korea, and via PCT filings through WIPO, reflecting international IP coverage. Commercial and clinical operations geography is not specified in the filing excerpts beyond U.S. regulatory interactions with the FDA.

Source: SEC 10-K, filed 2026-03-25

Industry: Pharmaceutical Preparations Peers: REGENERX BIOPHARMACEUTICALS INC Bio Path Holdings Inc eFFECTOR Therapeutics, Inc. Forte Biosciences Inc Vincerx Pharma, Inc. Oncotelic Therapeutics Inc Oncorus, Inc. Regulus Therapeutics Inc. Tonix Pharmaceuticals Holding Corp